Table 2 Patient, tumour and treatment characteristics (N = 42 patients)

Gender

Male

N = 16 (38.0%)

Female

N = 26 (62.0%)

Tumour stage

T4

N = 37 (88.1%)

T3

N = 1 (2.4%)

T2

N = 3 (7.1%)

T1

N = 1 (2.4%)

Site

Head

N = 36 (86.0%)

Body

N = 5 (12.0%)

Tail

N = 1 (2.0%)

PS (WHO)

0

N = 2 (5.0%)

1

N = 17 (41.0%)

2

N = 22 (52.0%)

3

N = 1 (2.0%)

Previous treatment

None

N = 8 (19.0%)

Chemotherapy only

N = 23 (54.8%)

Chemoradiotherapy

N = 4 (9.5%)

Palliative surgery (gastric/biliary bypass) + chemotherapy

N = 2 (4.8%)

Curative surgery (Whipples/Resection) + chemotherapy

N = 1 (2.4%)

Curative surgery (Whipples/Resection) + chemoradiotherapy

N = 4 (9.5%)

SABR purpose

PRIMARY

(no other/prior treatment)

N = 8 (19.0%)

ADJUVANT

(within 6 months other primary treatment)

N = 14 (33.3%)

CONSOLIDATION

(>  6 months post-primary treatment to residual disease)

N = 11 (26.2%)

RETREAT

(>  6 months post-primary treatment to disease relapse)

N = 9 (21.4%)